Jinju, South Korea

Gi Deok Park

This inventor holds 1 USPTO granted patent. Top assignee: Lactomason Co., Ltd.. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gi Deok Park: Innovator in Probiotic Strains

Introduction

Gi Deok Park is a notable inventor based in Jinju, South Korea. He has made significant contributions to the field of probiotics, particularly through his innovative research and development of mixed Bifidobacterium strains. His work focuses on enhancing the productivity and anti-inflammatory properties of these strains, which are essential for commercial viability in the probiotic market.

Latest Patents

Gi Deok Park holds a patent for a mixed Bifidobacterium strain with excellent productivity and anti-inflammatory activity. This patent includes subsp. LM1017 (Accession No. KCCM12629P), LM1092 (Accession No. KCCM13464P), LM1024 (Accession No. KCCM12919P), and LM1108 (Accession No. KCCM13463P). The strain he developed demonstrates exceptional commercial viability as a probiotic, making it a valuable asset in the health and wellness industry. He has 1 patent to his name.

Career Highlights

Gi Deok Park is currently associated with Lactomason Co., Ltd., where he continues to advance his research in probiotics. His work has garnered attention for its potential applications in improving gut health and overall well-being.

Collaborations

His coworker, Ye Ji You, has been instrumental in supporting his research endeavors. Together, they contribute to the innovative projects at Lactomason Co., Ltd.

Conclusion

Gi Deok Park's contributions to the field of probiotics through his patented innovations highlight his role as a key inventor in this area. His work not only enhances the understanding of Bifidobacterium strains but also paves the way for future advancements in probiotic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…